These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 8646551)
21. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer. Song K; Chang Y; Prud'homme GJ Gene Ther; 2000 Mar; 7(6):481-92. PubMed ID: 10757021 [TBL] [Abstract][Full Text] [Related]
22. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. Wu Y; Kipps TJ J Immunol; 1997 Dec; 159(12):6037-43. PubMed ID: 9550402 [TBL] [Abstract][Full Text] [Related]
23. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Lanuti M; Rudginsky S; Force SD; Lambright ES; Siders WM; Chang MY; Amin KM; Kaiser LR; Scheule RK; Albelda SM Cancer Res; 2000 Jun; 60(11):2955-63. PubMed ID: 10850443 [TBL] [Abstract][Full Text] [Related]
24. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity. Gordon LB; Nolan SC; Cserr HF; Knopf PM; Harling-Berg CJ J Immunol; 1997 Sep; 159(5):2399-408. PubMed ID: 9278331 [TBL] [Abstract][Full Text] [Related]
25. Inflammation and cancer, the mastocytoma P815 tumor model revisited: triggering of macrophage activation in vivo with pro-tumorigenic consequences. Kamate C; Baloul S; Grootenboer S; Pessis E; Chevrot A; Tulliez M; Marchiol C; Viguier M; Fradelizi D Int J Cancer; 2002 Aug; 100(5):571-9. PubMed ID: 12124807 [TBL] [Abstract][Full Text] [Related]
26. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes. Nagy E; Baral E; Kangas L; Berczi I Anticancer Res; 1997; 17(2A):1083-8. PubMed ID: 9137453 [TBL] [Abstract][Full Text] [Related]
27. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes. Yang G; Mizuno MT; Hellström KE; Chen L J Immunol; 1997 Jan; 158(2):851-8. PubMed ID: 8993003 [TBL] [Abstract][Full Text] [Related]
28. Targeting an anti-viral CD8+ T cell response to a growing tumor facilitates its rejection. Böhm W; Schirmbeck R; Reimann J Cancer Immunol Immunother; 1997 Jun; 44(4):230-8. PubMed ID: 9222282 [TBL] [Abstract][Full Text] [Related]
29. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. Fallarino F; Gajewski TF J Immunol; 1999 Oct; 163(8):4109-13. PubMed ID: 10510345 [TBL] [Abstract][Full Text] [Related]
30. Histopathologic analysis of intraocular allogeneic tumors in mice. Luckenbach MW; Streilein JW; Niederkorn JY Invest Ophthalmol Vis Sci; 1985 Oct; 26(10):1368-76. PubMed ID: 3930419 [TBL] [Abstract][Full Text] [Related]
31. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma. Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650 [TBL] [Abstract][Full Text] [Related]
32. High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer. Fernandez NC; Levraud JP; Haddada H; Perricaudet M; Kourilsky P J Immunol; 1999 Jan; 162(1):609-17. PubMed ID: 9886439 [TBL] [Abstract][Full Text] [Related]
33. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. Van den Eynde B; Lethé B; Van Pel A; De Plaen E; Boon T J Exp Med; 1991 Jun; 173(6):1373-84. PubMed ID: 1903428 [TBL] [Abstract][Full Text] [Related]
34. [Massive apoptosis in P815 mastocytoma in vivo induced by interleukin 2 gene transduction]. Guo N; Li X; Liu X Zhonghua Bing Li Xue Za Zhi; 1996 Oct; 25(5):284-7. PubMed ID: 9388873 [TBL] [Abstract][Full Text] [Related]
35. Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL. Silla S; Fallarino F; Boon T; Uyttenhove C Eur Cytokine Netw; 1999 Jun; 10(2):181-90. PubMed ID: 10400824 [TBL] [Abstract][Full Text] [Related]
36. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege. Chen PW; Uno T; Ksander BR Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898 [TBL] [Abstract][Full Text] [Related]
37. Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer. Cao X; Huang X; Ju DW; Zhang W; Hamada H; Wang J Cancer Gene Ther; 2000 Feb; 7(2):177-86. PubMed ID: 10770625 [TBL] [Abstract][Full Text] [Related]
38. [The synergistic action of lipopolysaccharide and muramyl dipeptide in the immunotherapy of DBA/2 mice with mastocytoma P815]. Rakhmilevich AL; Rakhimova MS Biull Eksp Biol Med; 1989 Dec; 108(12):721-4. PubMed ID: 2517487 [TBL] [Abstract][Full Text] [Related]
39. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Takeda K; Smyth MJ; Cretney E; Hayakawa Y; Yamaguchi N; Yagita H; Okumura K Cell Immunol; 2001 Dec; 214(2):194-200. PubMed ID: 12088418 [TBL] [Abstract][Full Text] [Related]
40. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells. Wahlsten JL; Mills CD; Ramakrishnan S J Immunol; 1998 Dec; 161(12):6761-7. PubMed ID: 9862706 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]